Topical Vaginal Estrogen in Postpartum Women: What a 2026 Systematic Review Actually Found

A new systematic review published in Acta Obstetricia et Gynecologica Scandinavica on May 4, 2026, by researchers in the Department of Urogynecology at King’s College Hospital in London, examines a question that comes up in postpartum clinics: should topical vaginal estrogen be considered for women navigating postpartum vaginal atrophy?

The background

Topical vaginal estrogens have a long track record in the management of postmenopausal vulvovaginal atrophy. The mechanism is straightforward — local estrogen is reintroduced to the estrogen-receptive tissues of the urogenital tract after systemic estrogen levels decline.

The authors point out that the postpartum period is, in some ways, biologically similar: raised prolactin levels during pregnancy and lactation antagonize estrogen, producing a state of relative estrogen depletion. This is thought to contribute to post-delivery pelvic floor dysfunction and vaginal atrophy. So in theory, topical vaginal estrogen might play a similar role in postpartum women that it does in postmenopausal women.

The review

The review was conducted per PRISMA guidelines, screening databases from inception through October 2025. After applying inclusion criteria, three studies covering a total of 85 women were eligible:

  • Two studies focused on the molecular and cellular composition of tissues from postpartum women using topical vaginal estrogens.
  • One double-blind randomized placebo-controlled trial primarily evaluated postpartum atrophy in the presence and absence of vaginal estrogens.

What they found

  • Tissue level: Tissues exposed to estrogen appeared to have increased cellular proliferation.
  • Symptom level: The Vulval Assessment Score (VuAS), a patient-subjective validated scoring system for vaginal atrophy, was lower (better) in women using vaginal estrogen cream for 12 weeks.
  • Bladder, bowel, sexual function: No statistically significant difference was found.
  • Safety: No serious adverse outcomes were reported. Use of vaginal estrogens appeared acceptable to women.

What the authors conclude

“There is a paucity of data currently available regarding the use of topical vaginal estrogens in the post-partum period. Although likely safe for use, further evidence is required to be able to make firm conclusions about their efficacy for postpartum vaginal atrophy, and further high-quality trials are required in the future.”

What this means for you

If you’re postpartum and experiencing vaginal dryness, tightness, or tissue changes — especially while breastfeeding — this review suggests topical vaginal estrogen may be worth a conversation with your provider. The evidence base is small (85 women across three studies), but the safety signal is reassuring and the symptom-level benefit on validated scoring was observed.

The authors’ caveat is important and worth saying directly: more research is needed. This isn’t a randomized trial of thousands of women. It’s a careful review of three small studies, all pointing in a similar direction.

A self-advocacy script

“I’m postpartum and noticing vaginal dryness and tissue changes. I’ve read that topical vaginal estrogen has been studied in postpartum women with reasonable safety. Can we discuss whether this is appropriate for me?”

Source

Waheed A, Taithongchai A, Robinson D. The use of topical vaginal estrogens in postpartum women: A systematic review. Acta Obstet Gynecol Scand. 2026 May 4. doi:10.1111/aogs.70241

This article is educational content. It is not medical advice and does not create a provider-patient relationship.